Home » Topics » BioWorld Science, Immune

BioWorld Science, Immune
RSS

Priority review status assigned to Rapamune immunosuppressive therapy

Feb. 3, 1999

New herpes vaccine from Cel-Sci proves effective in protecting mice

Feb. 1, 1999

OraVax, Peptide Therapeutics and Pasteur Merieux Connaught announce agreements

Feb. 1, 1999

Antex Biologics successfully completes phase I study of Helicobacter vaccine

Jan. 29, 1999

Yoshitomi's new immunosuppressive agents for arthritis, autoimmune diseases and transplant rejection

Jan. 27, 1999

Another significant market introduction for basiliximab

Jan. 25, 1999

Glaxo Wellcome and PowderJect expand DNA vaccine collaboration

Jan. 25, 1999

Alpha-Beta Technology discontinues phase III trial of Betafectin

Jan. 25, 1999

Cel-Sci and University of Maryland receive award for TB vaccine development

Jan. 22, 1999

Terprenin: novel immunosuppressant and antiallergic substance under evaluation at Shionogi

Jan. 22, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....